Navigation Links
XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
Date:6/30/2008

VALLEY COTTAGE, N.Y., June 30 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today announced that it has completed patient randomization into its Phase 2b study of Bicifadine -- a serotonin and norepinephrine reuptake inhibitor (SNRI) -- for the treatment of diabetic neuropathic pain. 350 patients were randomized into the study. Based on the completion of randomization, the Company expects to have the last patient complete the study in the next 4 months.

The Phase 2b trial is aimed at demonstrating the efficacy of Bicifadine in diabetic neuropathic pain, using a study design that is similar to the successful registration trials of Cymbalta(R), a member of the SNRI class that is approved for this indication, and other approved agents for neuropathic pain.

The Phase 2b study is a randomized, double-blind, placebo-controlled study comparing 200mg 3x/day (tid) and 400mg 3x/day (tid) of Bicifadine versus placebo, with a 1:1:1 randomization between the three arms, in patients with diabetic neuropathic pain. Approximately 40 clinical centers in the United States, Germany, Israel and India are participating in the study. Following randomization, all patients enter a 2-week titration period to allow them to gradually escalate up to their target treatment dose. This is followed by a 12-week steady-state treatment period at the target treatment dose. The primary endpoint of the study is to compare the efficacy of each of the two active doses of Bicifadine (200mg tid and 400mg tid) versus placebo in reduction of pain associated with diabetic neuropathy, at baseline (at the time of randomization) versus week 14 (week 12 of the steady-state phase). Pain is measured based on a 24-hour pain rating using the
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
9. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Legal-Bay LLC, the Lawsuit Settlement Funding Company, ... multidistrict litigation (MDL) over the Zimmer NexGen Knee implant ... , 2015. There are currently more than a thousand ... a federal judge in Illinois . ... begin in October of this year. Zimmer Inc. previously ...
(Date:6/29/2015)... -- , Gerresheimer will sell its borosilicate glass ... into a 10-year-supply agreement for pharmaceutical glass tubing ... Corning and Gerresheimer will form a joint ... Gerresheimer,s outlook for the financial years 2016 to ... tubing business , In line with its strategy ...
(Date:6/29/2015)... 29, 2015  PDL BioPharma, Inc. (NASDAQ: PDLI ... credit agreement with CareView Communications, Inc. (OTCQB: CRVW) whereby ... of secured debt financing. CareView is an information technology ... monitoring. Under the credit agreement, PDL will ... financing in two tranches of $20 million, based upon ...
Breaking Medicine Technology:Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3Gerresheimer Will Sell Tubing Operations to Corning - Both Will Form a Joint Venture to Accelerate Innovations for Pharmaceutical Glass Packaging Market 2Gerresheimer Will Sell Tubing Operations to Corning - Both Will Form a Joint Venture to Accelerate Innovations for Pharmaceutical Glass Packaging Market 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4
(Date:6/30/2015)... ... 30, 2015 , ... The board certified otolaryngologists at Clear ... to inform potential sinus surgery patients about ear, nose, and throat (ENT) ailments ... a wide variety of ENT issues including hearing loss, ear infections, dizziness, sleep ...
(Date:6/30/2015)... ... June 30, 2015 , ... Villa Health Care ... centers in the country. To spread the word, Villa Health Care Center created ... is, indeed, worthy of five stars. While Medicare centers its rating on health ...
(Date:6/30/2015)... ... 2015 , ... The LIV Fertility Center in Puerto Vallarta is ... age to pursue egg freezing. Statistics show that 20 percent of women are waiting ... percent increase since the 1970s. , Sadly, for women who have delayed parenthood for ...
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... 2007 to 2013 while heroin-related deaths more than tripled in the same period—leading a ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, asserts that ...
(Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, 2015 , ... ... Reasons You Have Acne ,” listed five triggers that most people would not ... cloths, hair care products, and toothpaste. The primary causes of acne are ...
Breaking Medicine News(10 mins):Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:Villa Health Care Center Announces Highest Care Rating in New Video 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2
... A recently published study revealed that virological breakthrough (VBT) ... chronic hepatitis B. Nearly 40% of the VBTs found ... this retrospective study are published in the May issue ... on behalf of the American Association for the Study ...
... drug memantine submitted a supplementary analysis of study data, the ... sees proof of a benefit of the drug for cognitive ... of daily living, at least for a treatment period of ... benefit assessment of 2009. IQWiG had repeatedly called upon the ...
... Goodwin HealthDay Reporter , TUESDAY, April 26 (HealthDay ... attacks, such as clot-busting drugs and rapid angioplasty, has led ... Researchers used data from a Swedish coronary care registry ... type of deadly heart attack known as STEMI between 1996 ...
... for publication in The Endocrine Society,s Journal of Clinical ... white children with vitamin D deficiency both had higher fat ... of fat just under their skin and white children were ... internal organs. Studies in adults and children have shown ...
... , TUESDAY, April 26 (HealthDay News) -- Seniors who ... of developing Alzheimer,s disease, a new study suggests. ... house causes dementia, and other factors could explain the ... cost of isolation, said lead investigator Bryan D. James, ...
... University bioengineering students in collaboration with the Texas Heart ... to arrhythmia victims headed toward cardiac arrest. For ... created a unique pad system for automated external defibrillators ... back into a proper rhythm in an emergency. ...
Cached Medicine News:Health News:Hepatitis B virus reemerges with long-term nucleoside analog treatment 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 3Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 3Health News:Vitamin D deficiency is associated with different types of obesity in black and white children 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 3Health News:Unique AED pads give hearts a second chance 2
For the quantitative determination of uric acid in serum....
For determination of uric acid in serum, plasma or urine. For Hitachi 704 / 911. Available with Calibrator: Trucal U and controls: Trulab N and Trulab P....
For the quantitative determination of uric acid in serum....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
Medicine Products: